drugset / Trial / NCT07296809
SKB500 Combinations in Patients With Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.
Timeline
- Start
- 2026-01-30
- Primary completion
- 2028-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | SKB500 | Unknown | — | Intravenous |
| Background | KL-A167 | Unknown | 1200 mg | Intravenous |